Literature DB >> 3785322

Inheritance pattern and clinical response to splenectomy as a reflection of erythrocyte spectrin deficiency in hereditary spherocytosis.

P Agre, A Asimos, J F Casella, C McMillan.   

Abstract

To determine how various inheritance patterns and responses to splenectomy relate to erythrocyte spectrin deficiencies in hereditary spherocytosis, we measured the spectrin content of erythrocytes by radioimmunoassay in 33 patients with this disease. Patients with the dominant form of hereditary spherocytosis generally had mild anemia, with spectrin at 63 to 81 percent of normal levels. Patients with the nondominant form of the disease had anemia ranging from severe to mild, with corresponding spectrin levels of 30 to 74 percent; their siblings were affected similarly. Distantly related homozygotes had different clinical severities with correspondingly different spectrin levels. The parents and offspring of patients with the nondominant form were clinically normal but consistently had subtle erythrocyte abnormalities. Spectrin levels in all patients were inversely related to osmotic fragility (P less than 0.0001), and they were also correlated with the clinical response to splenectomy: patients with spectrin levels above 70 percent achieved normal blood counts, those with levels of 40 to 70 percent had compensated hemolysis, and those with levels below 40 percent improved but remained anemic (P less than 0.0001). We conclude that the inheritance pattern and response to splenectomy in hereditary spherocytosis reflect erythrocyte spectrin deficiencies as determined by radioimmunoassay.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3785322     DOI: 10.1056/NEJM198612183152504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  30 in total

1.  Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children.

Authors:  Henry E Rice; Keith T Oldham; Cheryl A Hillery; Michael A Skinner; Sara M O'Hara; Russell E Ware
Journal:  Ann Surg       Date:  2003-02       Impact factor: 12.969

Review 2.  Current problems in haematology. 2: Hereditary spherocytosis.

Authors:  J C Smedley; A J Bellingham
Journal:  J Clin Pathol       Date:  1991-06       Impact factor: 3.411

3.  Spectrin/band 3 ratio as diagnostic tool in hereditary spherocytosis.

Authors:  S Cutillo; L Pinto; B Nobili; E Miraglia del Giudice; A Iolascon
Journal:  Eur J Pediatr       Date:  1992-01       Impact factor: 3.183

4.  An insulator with barrier-element activity promotes alpha-spectrin gene expression in erythroid cells.

Authors:  Patrick G Gallagher; Douglas G Nilson; Laurie A Steiner; Yelena D Maksimova; Jolinta Y Lin; David M Bodine
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

Review 5.  Abnormalities of the erythrocyte membrane.

Authors:  Patrick G Gallagher
Journal:  Pediatr Clin North Am       Date:  2013-10-15       Impact factor: 3.278

6.  Immunocytochemical study of membrane skeletons in abnormally shaped erythrocytes as revealed by a quick-freezing and deep-etching method.

Authors:  S Ohno; N Terada; Y Fujii; H Ueda; H Kuramoto; N Kamisawa
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

7.  Membrane skeleton involvement in cell fusion kinetics: a parameter that correlates with erythrocyte osmotic fragility.

Authors:  M Baumann; A E Sowers
Journal:  Biophys J       Date:  1996-07       Impact factor: 4.033

8.  Membrane protein lesions in erythrocytes with Heinz bodies.

Authors:  O S Platt; J F Falcone
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

9.  Reductions of erythrocyte membrane viscoelastic coefficients reflect spectrin deficiencies in hereditary spherocytosis.

Authors:  R E Waugh; P Agre
Journal:  J Clin Invest       Date:  1988-01       Impact factor: 14.808

10.  Abnormal oxidant sensitivity and beta-chain structure of spectrin in hereditary spherocytosis associated with defective spectrin-protein 4.1 binding.

Authors:  P S Becker; J S Morrow; S E Lux
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.